This study found that the consumption of antioxidants through dietary intake was correlated with reduced rates of infection or mucositis, with no increased risk of relapse or reduced survival.
The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies.
Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies.
Isolated Extramedullary Relapse in Acute Lymphoblastic Leukemia: What Can We Do Before and After Transplant?
The case of a 43-year-old male with a history of B-cell acute lymphoblastic leukemia.
Regardless of these improvements though, researchers noted that cancer survivors remain at risk for shorter lifespans, particularly when radiotherapy was utilized as a part of their childhood cancer treatment.
The ALL expert spoke about new research in the field and how it has changed the landscape for this disease.
This is the first cost-effectiveness analysis of the agent compared with the current standard of care using a constructed population-based control arm.
Combined with intensive chemotherapy, the next-generation inhibitor provided excellent results in pediatric patients with Philadelphia chromosome-positive ALL, leading to changes in how this population is treated.
This research has the potential to aid in the development of new strategies for early detection of relapse in pediatric patients with ALL, and the development of treatments to counter clinical occurrence.
This study indicated that caregivers saw improved quality of life, reduced caregiving burden, lower anxiety and depression symptoms, and improved self-efficacy and coping skills having received psychosocial intervention.